Experimenting with computing

M. Beynon,S. Russ

DOI: https://doi.org/10.1016/j.jal.2008.09.008

2008-12-01

Journal of Applied Logic

Abstract:

What problem does this paper attempt to address?

Biological activity of 1,4-dihydropyridine derivatives.

L. Fiszer-Maliszewska,J. Wieczorek,M. Mordarski,R. Balicki,L. Kaczmarek,P. Nantka-Namirski

Archivum Immunologiae et Therapiae Experimentalis

Abstract:Six new 1,4-dihydropyridine derivatives were evaluated in vitro for antimicrobial and cytotoxic effects and in vivo for antineoplastic activity. These compounds inhibited the growth of most of Gram-positive and Gram-negative bacteria at concentrations of 50 and 100 micrograms/ml. Concentrations effective against fungi were somewhat lower (25-50 micrograms/ml). The growth of mycobacteria was inhibited at concentrations of 3.1-25 micrograms/ml. Compound IV inhibited the growth of pathogenic mycobacteria including M. tuberculosis resistant to SM and INH at 3.1 or 6.2 micrograms/ml. In cytotoxicity assays, compound II, IV and V appeared the most active. However, none of the 1,4-dihydropyridine derivatives affected the survival time of mice with P388 and L1210 leukemias or melanoma B16. The growth of subcutaneous tumors of sarcoma 180 was inhibited by compounds I, III, IV and V. The effect was dose related.
Evolution of Mechanical Circulatory Support for advanced heart failure

Cathrine M Moeller,Andrea Fernandez Valledor,Daniel Oren,Gal Rubinstein,Gabriel T Sayer,Nir Uriel

DOI: https://doi.org/10.1016/j.pcad.2024.01.018

Abstract:This comprehensive review highlights the significant advancements in Left Ventricular Assist Device (LVAD) therapy, emphasizing its evolution from the early pulsatile flow systems to the cutting-edge continuous-flow devices, particularly the HeartMate 3 (HM3) LVAD. These advancements have notably improved survival rates, reduced complications, and enhanced the quality of life (QoL) for patients with advanced heart failure. The dual role of LVADs, as a bridge-to-transplantation and destination therapy is discussed, highlighting the changing trends and policies in their application. The marked reduction in hemocompatibility-related adverse events (HRAE) with the HM3 LVAD, compared to previous models signifies ongoing progress in the field. Challenges such as managing major infections are discussed, including innovative solutions like energy transfer systems aimed at eliminating external drivelines. It explores various LVAD-associated complications, including HRAE, infections, hemodynamic-related adverse events, and cardiac arrhythmias, and underscores emerging strategies for predicting post-implantation outcomes, fostering a more individualized patient care approach. Tools such as the HM3 risk score are introduced for predicting survival based on pre-implant factors, along with advanced imaging techniques for improved complication prediction. Additionally, the review highlights potential new technologies and therapies in LVAD management, such as hemodynamic ramp tests for optimal speed adjustment and advanced remote monitoring systems. The goal is to automate LVAD speed adjustments based on real-time hemodynamic measurements, indicating a shift towards more effective, patient-centered therapy. The review concludes optimistically that ongoing research and potential future innovations hold the promise of revolutionizing heart failure management, paving the way for more effective and personalized treatment modalities.
The Future of Durable Mechanical Circulatory Support – Emerging Technological Innovations and Considerations to Enable Evolution of the Field

Seraina A. Dual,Jennifer Cowger,Ellen Roche,Aditi Nayak

DOI: https://doi.org/10.1016/j.cardfail.2024.01.011

IF: 6.592

2024-03-02

Journal of Cardiac Failure

Abstract:The field of durable mechanical circulatory support (MCS) has undergone an incredible evolution over the past few decades, resulting in significant improvements in longevity and quality of life for advanced heart failure patients. Despite these successes, substantial opportunities for further improvements remain, including in pump design and ancillary technology, peri- and post-operative management, and the overall patient experience. Ideally, durable MCS devices would be fully implantable, automatically controlled, and minimize need for anticoagulation. Reliable and long term total artificial hearts for bi-ventricular support would be available; and surgical, peri- and post-operative management would be informed by the individual patient phenotype along with computational simulations. In this review, we summarize emerging technological innovations in these areas, focusing primarily on innovations in late preclinical or early clinical phases of study. We highlight important considerations that the MCS community of clinicians, engineers, industry partners and venture capital investors should consider to sustain evolution of the field.

cardiac & cardiovascular systems
Percutaneous Mechanical Circulatory Support in Acute Heart Failure Complicated with Cardiogenic Shock

Maria Parthena Xenitopoulou,Kyriaki Ziampa,Alexandros P. Evangeliou,Stergios Tzikas,Vasileios Vassilikos

DOI: https://doi.org/10.3390/jcm13092642

IF: 3.9

2024-05-01

Journal of Clinical Medicine

Abstract:Despite advancements in algorithms concerning the management of cardiogenic shock, current guidelines still lack the adequate integration of mechanical circulatory support devices. In recent years, more and more devices have been developed to provide circulatory with or without respiratory support, when conservative treatment with inotropic agents and vasopressors has failed. Mechanical circulatory support can be contemplated for patients with severe, refractory, or acute-coronary-syndrome-related cardiogenic shock. Through this narrative review, we delve into the differences among the types of currently used devices by presenting their notable advantages and inconveniences. We address the technical issues emerging while choosing the best possible device, temporarily as a bridge to another treatment plan or as a destination therapy, in the optimal timing for each type of patient. We also highlight the diverse implantation and removal techniques to avoid major complications such as bleeding and limb ischemia. Ultimately, we hope to shed some light in the gaps of evidence and the importance of conducting further organized studies around the topic of mechanical circulatory support when dealing with such a high mortality rate.

medicine, general & internal
Mechanical circulatory support devices in adults with congenital heart disease

Deen L. Garba,Susan Joseph,Ari Cedars

DOI: https://doi.org/10.1097/mot.0000000000001165

2024-09-04

Current Opinion in Organ Transplantation

Abstract:Mechanical circulatory support is used frequently as a method of stabilizing patients with end stage heart failure who are unable to safely await allograft availability. While this technology has been fundamentally important in supporting patients with normal cardiac anatomy, it is still used infrequently in adult patients with congenital heart disease and end-stage heart failure. Here, we review the data on mechanical circulatory support technology in this small but growing population of patients with chronic heart disease prone to the development of circulatory failure.

transplantation
External catheter immobilization improves wound healing in micropigs.

C. Gokoo,M. Lelah,W. Hauck,K. Burhop

DOI: https://doi.org/10.1097/00002480-198907000-00077

1989-07-01

ASAIO Transactions

Abstract:Recurrent traumatic damage by mechanical action is a major cause of catheter exit site problems in CAPD patients. The purpose of this study was to determine the efficacy of a new external immobilization device (Immobilizer) on wound healing characteristics at the catheter exit site. Sixteen Tenckhoff catheters were surgically implanted in four Yucatan micropigs (two catheters per flank). Immobilization devices were placed on one catheter on each side of each animal; the other catheter was allowed free movement. The devices were changed daily, and exit sites were examined for wound healing progress and infection. Fourteen days following implantation the animals were sacrificed, and the catheter exit sites explanted for histologic examination. The results of this study suggest that immobilization of catheters with this device improves wound healing at the exit site, as evidenced by decreased (p less than 0.05) marsupialization/epidermal down-growth (nonimmobilized 2.9 mm vs. immobilized 1.6 mm), and an increased (p less than 0.05) macrophage/epithelioid cell/giant cell response within the exit tract or in the Dacron cuff (granulomatous response histology score of 2.3 for immobilized vs. a histology score of 1.6 for nonimmobilized). Thus, use of this device may help reduce catheter exit site problems in CAPD patients.
Current Landscape of Temporary Mechanical Circulatory Support in Heart-Failure-Related Cardiogenic Shock

Panayotis K. Vlachakis,Panagiotis Theofilis,Ioannis Leontsinis,Maria Drakopoulou,Paschalis Karakasis,Evangelos Oikonomou,Christina Chrysohoou,Konstantinos Tsioufis,Dimitris Tousoulis

DOI: https://doi.org/10.3390/jcm13144120

IF: 3.9

2024-07-15

Journal of Clinical Medicine

Abstract:Acute heart failure (HF) presents a significant mortality burden, necessitating continuous therapeutic advancements. Temporary mechanical circulatory support (MCS) is crucial in managing cardiogenic shock (CS) secondary to acute HF, serving as a bridge to recovery or durable support. Currently, MCS options include the Intra-Aortic Balloon Pump (IABP), TandemHeart (TH), Impella, and Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO), each offering unique benefits and risks tailored to patient-specific factors and clinical scenarios. This review examines the clinical implications of recent advancements in temporary MCS, identifies knowledge gaps, and explores promising avenues for future research and clinical application. Understanding each device's unique attributes is crucial for their efficient implementation in various clinical scenarios, ultimately advancing towards intelligent, personalized support strategies.

medicine, general & internal
Longitudinal Trends in Sexual Behaviors with Advancing Age and Menopause Among Women With and Without HIV-1 Infection

Tonya N. Taylor,J. Weedon,E. Golub,S. Karpiak,M. Gandhi,Mardge H. Cohen,A. Levine,H. Minkoff,A. Adedimeji,L. Goparaju,S. Holman,T. Wilson

DOI: https://doi.org/10.1007/s10461-014-0901-1

2015-05-01

AIDS and Behavior

Abstract:
Maximum permitted transmit power of white space devices operating on TV spectrum

E. P. L. Almeida,F. de S. Chaves,R. Iida,E. Souza,R. Vieira

DOI: https://doi.org/10.1109/IMOC.2011.6169341

2011-10-01

Abstract:In order to have the White Spaces of the UHF broadcast band (470–790 MHz) in use by unlicensed users, new implementation challenges and special efforts still need to be done. Regulators can significantly impact the feasibility of implementation through requirements on sensing thresholds or by defining emission limits of unlicensed users. This paper addresses the emission limits of unlicensed users according to ECC approach, where the maximum output power is calculated for each location and for each device type/class. The problem of coexistence between white space devices and DTT broadcast service for the operation modes considered in CEPT is discussed and evaluated through simulations. With the obtained results, we discuss the relevancy of parameters stored in the geo-location database.
Cardiological Challenges Related to Long-Term Mechanical Circulatory Support for Advanced Heart Failure in Patients with Chronic Non-Ischemic Cardiomyopathy

Michael Dandel

DOI: https://doi.org/10.3390/jcm12206451

2023-10-10

Abstract:Long-term mechanical circulatory support by a left ventricular assist device (LVAD), with or without an additional temporary or long-term right ventricular (RV) support, is a life-saving therapy for advanced heart failure (HF) refractory to pharmacological treatment, as well as for both device and surgical optimization therapies. In patients with chronic non-ischemic cardiomyopathy (NICM), timely prediction of HF's transition into its end stage, necessitating life-saving heart transplantation or long-term VAD support (as a bridge-to-transplantation or destination therapy), remains particularly challenging, given the wide range of possible etiologies, pathophysiological features, and clinical presentations of NICM. Decision-making between the necessity of an LVAD or a biventricular assist device (BVAD) is crucial because both unnecessary use of a BVAD and irreversible right ventricular (RV) failure after LVAD implantation can seriously impair patient outcomes. The pre-operative or, at the latest, intraoperative prediction of RV function after LVAD implantation is reliably possible, but necessitates integrative evaluations of many different echocardiographic, hemodynamic, clinical, and laboratory parameters. VADs create favorable conditions for the reversal of structural and functional cardiac alterations not only in acute forms of HF, but also in chronic HF. Although full cardiac recovery is rather unusual in VAD recipients with pre-implant chronic HF, the search for myocardial reverse remodelling and functional improvement is worthwhile because, for sufficiently recovered patients, weaning from VADs has proved to be feasible and capable of providing survival benefits and better quality of life even if recovery remains incomplete. This review article aimed to provide an updated theoretical and practical background for those engaged in this highly demanding and still current topic due to the continuous technical progress in the optimization of long-term VADs, as well as due to the new challenges which have emerged in conjunction with the proof of a possible myocardial recovery during long-term ventricular support up to levels which allow successful device explantation.
Echocardiography and cardiac assist devices

E Catena,F Milazzo

Abstract:Mechanical circulatory support is, nowadays, a well established treatment modality for end stage heart failure. Patients candidate for cardiac transplantation who decompensate while awaiting graft can be supported by long-term left ventricular assist devices (long-term LVAD). These devices are intracorporeal pumps, expensive and complicated to install, but offer the advantages of a high cardiac output and a good patient mobility. Echocardiography is usually applied to any kind of LVAD to accomplish: preoperative evaluation to exclude contraindications, intraoperative when circulatory support starts to assess left ventricular (LV) filling and unloading, postoperative evaluation during intensive care unit course to prevent hypovolemia, cardiac tamponade and right ventricular failure, controls during assistance for suspected device malfunction. Short-term devices are utilized as acute support after the initial resuscitation of the patient. These devices are bedside extracorporeal pumps, less expensive and less complicated to install. They provide a brief but sufficient time to wait patient recovery (''bridge to recovery'') or to evaluate further therapies (''bridge to long-term device'' or ''bridge to transplantation''). Echocardiography has an important role during implantation to guide cannulae positioning, to prevent insufficient LV unloading, to detect echo contrast enhancement with blood stagnation and intracardiac clot formation, to titrate pharmacologic support, and to assess myocardial recovery.
Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.

R. Crocchiolo,L. Castagna,J. El-Cheikh,A. Helvig,S. Fürst,C. Faucher,A. Vazquez,A. Granata,D. Coso,R. Bouabdallah,D. Blaise

DOI: https://doi.org/10.1016/j.exphem.2011.06.006

IF: 3.249

2011-09-01

Experimental Hematology

Abstract:
Rotary mechanical circulatory support systems

Milad Hosseinipour,Rajesh Gupta,Mark Bonnell,Mohammad Elahinia

DOI: https://doi.org/10.1177/2055668317725994

2017-09-25

Abstract:A detailed survey of the current trends and recent advances in rotary mechanical circulatory support systems is presented in this paper. Rather than clinical reports, the focus is on technological aspects of these rehabilitating devices as a reference for engineers and biomedical researchers. Existing trends in flow regimes, flow control, and bearing mechanisms are summarized. System specifications and applications of the most prominent continuous-flow ventricular assistive devices are provided. Based on the flow regime, pumps are categorized as axial flow, centrifugal flow, and mixed flow. Unique characteristics of each system are unveiled through an examination of the structure, bearing mechanism, impeller design, flow rate, and biocompatibility. A discussion on the current limitations is provided to invite more studies and further improvements.

Medical Physics
Perspective: Will blood-informed design signal the fourth generation of cardiac assist devices?

Michael J Simmonds,Bente Thamsen,Salim E Olia,Antony P McNamee,Marcus Granegger,Hendrik Wurm,Keshava Rajagopal,David C McGiffin

DOI: https://doi.org/10.1016/j.healun.2024.08.011

2024-08-23

Abstract:Mechanical circulatory support devices have profoundly transformed the management of severe cardiothoracic disorders. While heart transplantation is the gold standard therapy for end stage heart disease, long-term mechanical support devices are a viable alternative for those ineligible and/or those awaiting organ availability. Major technological advancements were made over first five decades of development, resulting in improved durability and survival with reduced adverse events. However, gains have tapered recently for various complications (e.g., internal bleeding; multi-system organ failure) which collectively represent a significant proportion of disability and/or mortality. Further, in light of mature ventricular assist devices failing during clinical trials or even after clinical approval (Class I withdrawals), it is timely to consider: are our pre-clinical assessment protocols, vital in the design and development of mechanical circulatory support devices, providing a realistic and reliable profile of future clinical performance? This commentary explores this question and analyses development pathways through the lens of the various disciplines involved in the pre-clinical assessment of mechanical circulatory support technologies: limitations in approaches to benchtop blood testing, computational design and simulation, and animal testing are discussed as likely contributors to some of the common hemocompatibility-related adverse events. While it is acknowledged that some shortcomings are pragmatic in nature, possible solutions are presented that will only be realised through truly transdisciplinary and open approaches that challenge the current nature of medical device development. We suggest that these can and must be overcome to diminish hemocompatibility-related adverse events and will potentially demarcate the fourth-generation of cardiac assist devices.
The HeartSaver left ventricular assist device: an update

P J Hendry,T V Mussivand,R G Masters,M E Bourke,G M Guiraudon,K S Holmes,K D Day,W J Keon

DOI: https://doi.org/10.1016/s0003-4975(00)02613-8

Abstract:Background: Ventricular assist devices have been shown to be effective as bridges to transplantation and recovery for patients with end-stage heart failure. Current technology has been limited because of the need for percutaneous connections with controllers. The HeartSaver ventricular assist device (VAD) (World Heart Corporation, Ottawa, Ontario, Canada) was developed with the intention of having a completely implantable, portable VAD system. The system consists of an electrohydraulic blood pump, internal and external battery power, and a transcutaneous energy transfer and telemetry unit that allows for power transmission through the skin. Control of the device may be achieved locally or remotely through a variety of communication systems. Methods: The device has been modified with the Series II preclinical version being available for in vitro (mock loop) and in vivo (bovine model) testing. Results: Seventeen Series II devices have been functional on mock loops or other testing trials for an accumulated 900 days of operation. There have been eight acute experiments using a bovine model to test various components as they have become available from manufacturing. Mean pump output was 10.4 +/- 1.1 L/min in full-fill/full-eject mode. Changes in the last 24 months include (1) cannula redesign for better port alignment and integration of tissue valves; (2) battery redesign to convert to new lithium-ion cells; (3) optimized infrared information and electromagnetic inductance energy transmission through various skin thicknesses and pigmentation; and (4) improved reliability of internal and external controller hardware and software. Conclusions: Modifications have been required to optimize the HeartSaver VAD's performance. The final HeartSaver VAD design will be produced in the near future to allow for formal in vitro and in vivo testing before clinical implantation.
Special Considerations for Mechanical Circulatory Support or Device Therapy in Adult Congenital Heart Disease Heart Failure

Rafael Alonso-Gonzalez,Guillermo Agorrody

DOI: https://doi.org/10.1016/j.hfc.2023.12.003

IF: 3.4

2024-01-01

Heart Failure Clinics

Abstract:Heart failure has become the leading cause of mortality in adult congenital heart disease (ACHD) patients after the fifth decade of life. There is scanty evidence supporting the use of guideline-directed medical therapy in ACHD, especially in systemic right ventricle or single ventricle physiology. In complex patients, diagnosing heart failure and timely referral for advanced therapies are challenging. Mechanical circulatory support has been significantly developed over the past decade and has recently emerged as a feasible therapeutic option for these patients. This review summarizes current evidence of mechanical circulatory support in this population, its potential uses, and challenges.

cardiac & cardiovascular systems
Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.

S. Doi,N. Woodhouse

Clinical Endocrinology

Abstract:AIMS To compare the efficacy of remnant ablation following a single low dose (specific activity of 131I administered, 1074-1110 MBq) vs. a single high dose (mostly 2775-3700 MBq) of 131I in patients with differentiated thyroid cancer and to determine whether or not the extent of surgery influences outcome. METHODS Nineteen studies have reported the results of low dose 131I ablation. Of these, 11 met our criteria for a comparative analysis. Two additional cohorts of ours were added and these were analysed in two groups based on the extent of surgery (near-total [NT; Woodhouse1] vs. sub-total [ST; Woodhouse2]). There were 518 low dose and 449 high dose patients in all. RESULTS The average failure of a single low dose was 46 +/- 28% (SD). Meta-analysis revealed a statistically significant advantage for a single high over a single low dose and a pooled reduction in relative risk of failure of the high dose of about 27% (P < 0.01). From this we estimate that for every seven patients treated one more would be ablated given a high rather than a low dose (assuming a low dose failure risk of 50%). Also, a significantly greater proportion of patients are ablated after a single high or low dose, if they underwent near-total as opposed to sub-total thyroidectomy (summary relative risk (RR) 1.4; P < 0.05). CONCLUSION High dose 131I is more efficient than low dose for remnant ablation particularly after less than total thyroidectomy. Results suggest that patients with differentiated thyroid cancer should routinely have a total thyroidectomy followed by high dose 131I (2775-3700MBq) for ablation of the remnant.
Durable left ventricular assist devices: a contemporary review of their benefits and drawbacks

Max Shin,Nikhil Ganjoo,Omar Toubat,Rohan Shad,Pavan Atluri

DOI: https://doi.org/10.1080/17434440.2024.2433716

IF: 3.439

2024-12-04

Expert Review of Medical Devices

Abstract:Introduction Heart transplantation, the gold standard for end-stage cardiomyopathy, is hindered by donor shortages and clinical deterioration. Left ventricular assist devices (LVADs) have emerged as crucial alternatives, stabilizing hemodynamics, reversing end-organ damage, and enabling patient discharge. Significant engineering advancements and iterative improvements have since produced devices capable of rivaling heart transplantation in early survival potential. This review serves to provide an overview of LVAD technology, an understanding of current device limitations, and preview new technologies being developed to address them.

engineering, biomedical
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

S. Choquet,V. Leblond,R. Herbrecht,G. Socié,A. Stoppa,P. Vandenberghe,A. Fischer,F. Morschhauser,G. Salles,W. Feremans,E. Vilmer,M. Peraldi,P. Lang,Y. Lebranchu,É. Oksenhendler

DOI: https://doi.org/10.1182/BLOOD-2005-01-0377

IF: 20.3

2006-04-15

Blood

Abstract:B-cell posttransplantation lymphoproliferative disorder (B-PTLD) is a rare but severe complication of transplantation, with no consensus on best treatment practice. This prospective trial, the first to test a treatment for PTLD, was designed to evaluate the efficacy and safety of rituximab in patients with B-PTLD after solid organ transplantation (SOT). Forty-six patients were included and 43 patients were analyzed. Patients were eligible if they had untreated B-PTLD that was not responding to tapering of immunosuppression. Treatment consisted of 4 weekly injections of rituximab at 375 mg/m2. At day (d) 80, 37 (86%) patients were alive, and the response rate was 44.2%, including 12 complete response/unconfirmed complete response (CR/CRu). The only factor predictive of a response at d80 was a normal lactate dehydrogenase level (P = .007, odds ratio [OR] = 6.9). At d360, responses were maintained in 68% of patients, and 56% of patients were alive. The overall survival rate at 1 year was 67%. We conclude that rituximab is effective and safe in PTLD, with stable responses at 1 year. The response rate and overall survival might be improved by combining rituximab with other treatments.
Common Complications and Cardiopulmonary Resuscitation in Patients with Left Ventricular Assist Devices: A Narrative Review

Jerica Zaloznik Djordjevic,Timur Özkan,Eva Göncz,Jus Ksela,Martin Möckel,Matej Strnad

DOI: https://doi.org/10.3390/medicina59111981

2023-11-10

Abstract:Heart failure remains a major global burden regarding patients' morbidity and mortality and health system organization, logistics, and costs. Despite continual advances in pharmacological and resynchronization device therapy, it is currently well accepted that heart transplantation and mechanical circulatory support represent a cornerstone in the management of advanced forms of this disease, with the latter becoming an increasingly accepted treatment modality due to the ongoing shortage of available donor hearts in an ever-increasing pool of patients. Mechanical circulatory support strategies have seen tremendous advances in recent years, especially in terms of pump technology improvements, indication for use, surgical techniques for device implantation, exchange and explantation, and postoperative patient management, but not in the field of treatment of critically ill patients and those undergoing cardiac arrest. This contemporary review aims to summarize the collected knowledge of this topic with an emphasis on complications in patients with left ventricular assist devices, their treatment, and establishing a clear-cut algorithm and the latest recommendations regarding out-of-hospital or emergency department management of cardiac arrest in this patient population.

Experimenting with computing

Biological activity of 1,4-dihydropyridine derivatives.

Evolution of Mechanical Circulatory Support for advanced heart failure

The Future of Durable Mechanical Circulatory Support – Emerging Technological Innovations and Considerations to Enable Evolution of the Field

Percutaneous Mechanical Circulatory Support in Acute Heart Failure Complicated with Cardiogenic Shock

Mechanical circulatory support devices in adults with congenital heart disease

External catheter immobilization improves wound healing in micropigs.

Current Landscape of Temporary Mechanical Circulatory Support in Heart-Failure-Related Cardiogenic Shock

Longitudinal Trends in Sexual Behaviors with Advancing Age and Menopause Among Women With and Without HIV-1 Infection

Maximum permitted transmit power of white space devices operating on TV spectrum

Cardiological Challenges Related to Long-Term Mechanical Circulatory Support for Advanced Heart Failure in Patients with Chronic Non-Ischemic Cardiomyopathy

Echocardiography and cardiac assist devices

Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients.

Rotary mechanical circulatory support systems

Perspective: Will blood-informed design signal the fourth generation of cardiac assist devices?

The HeartSaver left ventricular assist device: an update

Special Considerations for Mechanical Circulatory Support or Device Therapy in Adult Congenital Heart Disease Heart Failure

Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer.

Durable left ventricular assist devices: a contemporary review of their benefits and drawbacks

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study.

Common Complications and Cardiopulmonary Resuscitation in Patients with Left Ventricular Assist Devices: A Narrative Review